Editor Profile
Dr. Haoran Nie, Ph.D.
Researcher
Present
China Medical University
Shenyang
China
Haoran Nie, Ph.D.
Current Position:China Medical University, Shenyang, China.
Email: n931317196@163.com
Education
2025.9–present Ph.D. Tissue Engineering, China Medical University.
2022.9-2025.6 M.Sc. Medicinal Chemistry, Shandong Medical University.
2018.9-2022.6 M.B.B.S. Pharmaceutics, North Henan Medical University.
Professional Experience
2022.3-2022.6 Organic Chemistry Assistant Scientist, WuXi AppTec.
I focus on the design and synthesis of tyrosine kinase inhibitors and their antitumor activity. My work primarily involves developing novel compounds, investigating tumor mechanisms, and exploring innovative drug delivery strategies for cancer therapy. I have published 8 SCI papers in these related fields.
- Design, synthesis, and activity evaluation of tyrosine kinase inhibitors
- Biomedical nanomaterials for drug delivery and cancer therapy
- Targeted drug delivery systems and tumor therapy strategies
- Nie, H., et al. (2025). Synthesis of novel deuterated EGFR/ALK dual-target inhibitors and their activity against non-small cell lung cancer. European Journal of Medicinal Chemistry, 283, 117146. doi:10.1016/j.ejmech.2024.117146.
- Liu, J., Nie, W., Nie, H., et al. (2024). The new N2, N4-diphenylpyridine-2,4-diamine deuterated derivatives as EGFR inhibitors to overcome C797S-mediated resistance. Bioorganic Chemistry, 146, 107313. doi:10.1016/j.bioorg.2024.107313.
- An, B., Nie, W., Hu, J., Fan, Y., Nie, H., et al. (2023). A novel c-Met/TRK inhibitor 1D228 efficiently inhibits tumor growth by targeting angiogenesis and tumor cell proliferation. Cell Death & Disease, 14(11), 728. Published Nov 9, 2023. doi:10.1038/s41419-023-06246-5.
